Logo image of SKYE

SKYE BIOSCIENCE INC (SKYE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SKYE - US83086J2006 - Common Stock

0.9806 USD
+0.01 (+0.79%)
Last: 1/21/2026, 8:00:03 PM
1 USD
+0.02 (+1.98%)
After Hours: 1/21/2026, 8:00:03 PM
Fundamental Rating

2

Taking everything into account, SKYE scores 2 out of 10 in our fundamental rating. SKYE was compared to 525 industry peers in the Biotechnology industry. SKYE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SKYE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SKYE has reported negative net income.
  • In the past year SKYE has reported a negative cash flow from operations.
  • SKYE had negative earnings in each of the past 5 years.
  • SKYE had a negative operating cash flow in each of the past 5 years.
SKYE Yearly Net Income VS EBIT VS OCF VS FCFSKYE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -123.97%, SKYE is doing worse than 79.43% of the companies in the same industry.
  • The Return On Equity of SKYE (-156.02%) is worse than 64.76% of its industry peers.
Industry RankSector Rank
ROA -123.97%
ROE -156.02%
ROIC N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKYE Yearly ROA, ROE, ROICSKYE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SKYE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SKYE Yearly Profit, Operating, Gross MarginsSKYE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for SKYE has been increased compared to 1 year ago.
  • SKYE has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SKYE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SKYE Yearly Shares OutstandingSKYE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SKYE Yearly Total Debt VS Total AssetsSKYE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -7.14, we must say that SKYE is in the distress zone and has some risk of bankruptcy.
  • SKYE's Altman-Z score of -7.14 is on the low side compared to the rest of the industry. SKYE is outperformed by 65.71% of its industry peers.
  • There is no outstanding debt for SKYE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.14
ROIC/WACCN/A
WACCN/A
SKYE Yearly LT Debt VS Equity VS FCFSKYE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • SKYE has a Current Ratio of 4.77. This indicates that SKYE is financially healthy and has no problem in meeting its short term obligations.
  • SKYE has a Current ratio (4.77) which is comparable to the rest of the industry.
  • SKYE has a Quick Ratio of 4.77. This indicates that SKYE is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.77, SKYE is in line with its industry, outperforming 56.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.77
SKYE Yearly Current Assets VS Current LiabilitesSKYE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

  • SKYE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -218.02%.
EPS 1Y (TTM)-218.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -19.84% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-97.29%
EPS Next 2Y-23.01%
EPS Next 3Y-18.36%
EPS Next 5Y-19.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SKYE Yearly Revenue VS EstimatesSKYE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 100M 200M 300M
SKYE Yearly EPS VS EstimatesSKYE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SKYE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKYE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKYE Price Earnings VS Forward Price EarningsSKYE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SKYE Per share dataSKYE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • SKYE's earnings are expected to decrease with -18.36% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.01%
EPS Next 3Y-18.36%

More info and screens

0

5. Dividend

5.1 Amount

  • SKYE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SKYE BIOSCIENCE INC

NASDAQ:SKYE (1/21/2026, 8:00:03 PM)

After market: 1 +0.02 (+1.98%)

0.9806

+0.01 (+0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-18
Inst Owners62.92%
Inst Owner Change0%
Ins Owners1.52%
Ins Owner Change0%
Market Cap31.44M
Revenue(TTM)N/A
Net Income(TTM)-51.23M
Analysts81.43
Price Target8.89 (806.59%)
Short Float %3.16%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-370.59%
Min EPS beat(2)-746.82%
Max EPS beat(2)5.65%
EPS beat(4)3
Avg EPS beat(4)-179.91%
Min EPS beat(4)-746.82%
Max EPS beat(4)17.2%
EPS beat(8)4
Avg EPS beat(8)-91.51%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-41.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS1.02
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -123.97%
ROE -156.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.77
Altman-Z -7.14
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)207.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-218.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
EPS Next Y-97.29%
EPS Next 2Y-23.01%
EPS Next 3Y-18.36%
EPS Next 5Y-19.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-97.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-183.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-176.83%
OCF growth 3YN/A
OCF growth 5YN/A

SKYE BIOSCIENCE INC / SKYE FAQ

What is the fundamental rating for SKYE stock?

ChartMill assigns a fundamental rating of 2 / 10 to SKYE.


Can you provide the valuation status for SKYE BIOSCIENCE INC?

ChartMill assigns a valuation rating of 0 / 10 to SKYE BIOSCIENCE INC (SKYE). This can be considered as Overvalued.


Can you provide the profitability details for SKYE BIOSCIENCE INC?

SKYE BIOSCIENCE INC (SKYE) has a profitability rating of 0 / 10.


Can you provide the financial health for SKYE stock?

The financial health rating of SKYE BIOSCIENCE INC (SKYE) is 6 / 10.